Page last updated: 2024-08-21

thiazoles and Mole, Skin

thiazoles has been researched along with Mole, Skin in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (66.67)	24.3611
2020's	1 (33.33)	2.80

Authors

Authors	Studies
Garreta Fontelles, G; Grande Moreillo, C; Pardo Pastor, J	1
Amiel, J; Berteloot, L; Blanc, E; Blanc, T; Boccara, O; Boddaert, N; Bole-Feysot, C; Broissand, C; Canaud, G; Chaussain, C; Cormier-Daire, V; Duong, JP; Grenier, N; Guibaud, L; Hoguin, C; Johnson, SC; Joly, D; Knebelmann, B; Ladraa, S; Laroche-Raynaud, C; Legendre, C; Lyonnet, S; Magassa, S; Martinez, F; Merville, P; Michot, C; Pannier, S; Picard, A; Rabia, SH; Sadoine, J; Sarnacki, S; Slimani, L; Soupre, V; Terzi, F; Venot, Q; Yamaguchi, J	1
Delgado, C; Díaz, M; Lizarraga, R; López Gutiérrez, JC; Martínez Urrutia, MJ; Miguel, M; Triana, P	1

Trials

1 trial(s) available for thiazoles and Mole, Skin

Article	Year
Targeted therapy in patients with PIK3CA-related overgrowth syndrome. Nature, 2018, Volume: 558, Issue:7711 Topics: Adult; Animals; Child; Class I Phosphatidylinositol 3-Kinases; Disease Models, Animal; Female; Heart Failure; HeLa Cells; Humans; Lipoma; Male; Mice; Molecular Targeted Therapy; Musculoskeletal Abnormalities; Nevus; Phenotype; Scoliosis; Sirolimus; Syndrome; Thiazoles; Vascular Malformations; Vascular Neoplasms	2018

Article

Year

Targeted therapy in patients with PIK3CA-related overgrowth syndrome.

Nature, 2018, Volume: 558, Issue:7711

Topics: Adult; Animals; Child; Class I Phosphatidylinositol 3-Kinases; Disease Models, Animal; Female; Heart Failure; HeLa Cells; Humans; Lipoma; Male; Mice; Molecular Targeted Therapy; Musculoskeletal Abnormalities; Nevus; Phenotype; Scoliosis; Sirolimus; Syndrome; Thiazoles; Vascular Malformations; Vascular Neoplasms

2018

Other Studies

2 other study(ies) available for thiazoles and Mole, Skin

Article	Year
Alpelisib to treat CLOVES syndrome, a member of the PIK3CA-related overgrowth syndrome spectrum. British journal of clinical pharmacology, 2022, Volume: 88, Issue:8 Topics: Catalytic Domain; Class I Phosphatidylinositol 3-Kinases; Growth Disorders; Humans; Lipoma; Musculoskeletal Abnormalities; Mutation; Nevus; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Syndrome; Thiazoles; Vascular Malformations	2022
Alpelisib Treatment for Genital Vascular Malformation in a Patient with Congenital Lipomatous Overgrowth, Vascular Malformations, Epidermal Nevi, and Spinal/Skeletal Anomalies and/or Scoliosis (CLOVES) Syndrome. Journal of pediatric and adolescent gynecology, 2019, Volume: 32, Issue:6 Topics: Adolescent; Class I Phosphatidylinositol 3-Kinases; Female; Genitalia, Female; Humans; Lipoma; Musculoskeletal Abnormalities; Nevus; Protein Kinase Inhibitors; Thiazoles; Vascular Malformations	2019

Article

Year

Alpelisib to treat CLOVES syndrome, a member of the PIK3CA-related overgrowth syndrome spectrum.

British journal of clinical pharmacology, 2022, Volume: 88, Issue:8

Topics: Catalytic Domain; Class I Phosphatidylinositol 3-Kinases; Growth Disorders; Humans; Lipoma; Musculoskeletal Abnormalities; Mutation; Nevus; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Syndrome; Thiazoles; Vascular Malformations

2022

Alpelisib Treatment for Genital Vascular Malformation in a Patient with Congenital Lipomatous Overgrowth, Vascular Malformations, Epidermal Nevi, and Spinal/Skeletal Anomalies and/or Scoliosis (CLOVES) Syndrome.

Journal of pediatric and adolescent gynecology, 2019, Volume: 32, Issue:6

Topics: Adolescent; Class I Phosphatidylinositol 3-Kinases; Female; Genitalia, Female; Humans; Lipoma; Musculoskeletal Abnormalities; Nevus; Protein Kinase Inhibitors; Thiazoles; Vascular Malformations

2019